Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of SAL0150 tablets in adults with inadequately controlled type 2 diabetes mellitus
CTR20263725Phase 2Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SAL015 in type 2 diabetes mellitus (T2DM), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Oct 2026; status: active.
02
Drugs
SAL015
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20263725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263725.